News | July 07, 2022
Lonza to build large-scale fill & finish facility in Switzerland
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
Company is investing more than €100 million in the expansion of the Halle site
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The AICVD tool can predict the risk of cardiovascular disease.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
People in India are still wary of organ transplants. So, there is an urgent need of increased public awareness.
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
_256_384.jpg){kind=logo}
Meets the growing need for US-based API solubility and bioavailability enhancement services
Subscribe To Our Newsletter & Stay Updated
